BioMarin Pharmaceutical, Inc. (BMRN)
64.46
-0.83
(-1.27%)
USD |
NASDAQ |
Aug 28, 15:42
BioMarin Pharmaceutical Cash from Operations (Quarterly) : 168.11M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 168.11M |
| March 31, 2026 | 220.65M |
| December 31, 2025 | 99.64M |
| September 30, 2025 | 368.68M |
| June 30, 2025 | 185.27M |
| March 31, 2025 | 174.39M |
| December 31, 2024 | 185.63M |
| September 30, 2024 | 221.48M |
| June 30, 2024 | 118.76M |
| March 31, 2024 | 46.97M |
| December 31, 2023 | 27.48M |
| September 30, 2023 | 135.65M |
| June 30, 2023 | 70.06M |
| March 31, 2023 | -73.93M |
| December 31, 2022 | 6.786M |
| September 30, 2022 | 158.32M |
| June 30, 2022 | 56.23M |
| March 31, 2022 | -45.43M |
| December 31, 2021 | 11.18M |
| September 30, 2021 | 97.06M |
| June 30, 2021 | 82.78M |
| March 31, 2021 | 113.51M |
| December 31, 2020 | -13.38M |
| September 30, 2020 | 86.21M |
| June 30, 2020 | 27.74M |
| Date | Value |
|---|---|
| March 31, 2020 | -15.19M |
| December 31, 2019 | 57.34M |
| September 30, 2019 | 70.12M |
| June 30, 2019 | -24.34M |
| March 31, 2019 | -54.87M |
| December 31, 2018 | 49.37M |
| September 30, 2018 | 47.20M |
| June 30, 2018 | -33.86M |
| March 31, 2018 | -42.51M |
| December 31, 2017 | 14.61M |
| September 30, 2017 | 38.29M |
| June 30, 2017 | 18.78M |
| March 31, 2017 | -80.44M |
| December 31, 2016 | -0.21M |
| September 30, 2016 | -10.37M |
| June 30, 2016 | -45.80M |
| March 31, 2016 | -171.45M |
| December 31, 2015 | -68.20M |
| September 30, 2015 | -2.85M |
| June 30, 2015 | -12.83M |
| March 31, 2015 | -137.97M |
| December 31, 2014 | -26.78M |
| September 30, 2014 | -9.03M |
| June 30, 2014 | -11.53M |
| March 31, 2014 | -26.87M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Incyte Corp. | 507.66M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
| Ionis Pharmaceuticals, Inc. | 565.53M |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -5.102B |
| Cash from Financing (Quarterly) | 2.738B |
| Free Cash Flow | 725.08M |
| Free Cash Flow Per Share (Quarterly) | 0.6883 |
| Free Cash Flow to Equity (Quarterly) | -2.638B |
| Free Cash Flow to Firm (Quarterly) | 180.02M |
| Free Cash Flow Yield | 5.80% |